What happened with RPRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Royalty Pharma plc provides capital to universities, research institutions and drug companies by buying their rights to future drug-sales payments or funding development in exchange for new rights. Most of its portfolio consists of royalty rights bought from existing holders. Drug marketers’ sales generate the payments: Royalty Pharma generally receives a contractual share of sales, not profits, and uses cash from existing royalties to buy new investments.
The portfolio covers marketed medicines and development-stage candidates. Vertex’s cystic fibrosis medicines, including Trikafta/Kaftrio and Alyftrek, are its largest income source, and a handful of leading product franchises generate most royalty receipts. Royalty Pharma is disputing Vertex’s payments on Alyftrek, which it believes fall short of its contractual entitlement.
The companies developing and marketing the medicines generally control trials, approvals, manufacturing and sales; Royalty Pharma generally cannot direct their work. Its income therefore depends on their ability to bring medicines to market and sustain sales. Development-stage investments may never reach approval or generate royalties.
To remain outside U.S. investment-company regulation, Royalty Pharma and its subsidiaries must maintain a qualifying asset mix under the exclusions they rely on. This limits which assets they can hold or acquire.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Royalty Pharma depends on its portfolio’s drug sales and development outcomes, so also watch Roche’s Evrysdi and privately held Servier’s Voranigo, whose marketers are missing from this list.
Vertex sells cystic fibrosis medicines and pays Royalty Pharma a share of sales, making it the source of Royalty Pharma’s largest franchise. Watch Alyftrek’s royalty dispute: Vertex says the rate is 4%, while Royalty Pharma seeks approximately 8%.
Ligand competes with Royalty Pharma to fund drug developers and buy rights to a share of medicine sales. Its royalty purchases and development financing show where a rival is putting capital to build future royalty income.
GSK’s sales of the respiratory medicine Trelegy feed Royalty Pharma’s sales-based payments, contributing $332 million of receipts in 2025. Trelegy sales are the GSK revenue line to watch for this exposure.
Biogen’s Tysabri and Spinraza sales generate royalties for Royalty Pharma, which also funds Biogen’s litifilimab development. Watch those two medicines’ sales and litifilimab’s progress: Royalty Pharma provided $200 million of development funding in 2025.
Johnson & Johnson’s sales of Tremfya and jointly marketed Imbruvica support Royalty Pharma’s royalty income; together they generated $348 million of receipts in 2025. Tremfya sales forecasts matter beyond cash receipts: higher forecasts helped lift Royalty Pharma’s expected royalty cash flows in 2025.
Revolution Medicines receives up to $2 billion from Royalty Pharma through rights to future daraxonrasib sales and a secured loan, tying Royalty Pharma to this cancer drug’s success. FDA approval is a key event to watch because it requires Revolution Medicines to draw the first loan tranche.
Cytokinetics receives launch financing from Royalty Pharma and has sold it shares of revenue from MYQORZO, omecamtiv mecarbil and ulacamten. Watch MYQORZO’s U.S. sales to its focused cardiology customer base as Cytokinetics turns its launch into revenue.
Pfizer co-markets Xtandi, so sales of this prostate cancer medicine feed Royalty Pharma’s royalties and generated $197 million of receipts in 2025. Higher Xtandi forecasts also increased Royalty Pharma’s expected royalty cash flows that year.
Novartis sells Promacta/Revolade under an agreement with Royalty Pharma, which collects a share of those medicine sales. Promacta generated $142 million of Royalty Pharma’s receipts in 2025, making its sales the relevant Novartis revenue line to follow.
AbbVie co-markets Imbruvica, whose sales generated $170 million of Royalty Pharma’s receipts in 2025. Watch Imbruvica sales amid competition from other blood cancer treatments, rather than treating AbbVie’s overall results as a proxy for these royalties.
Amgen’s Imdelltra sales and olpasiran development matter to Royalty Pharma, which owns royalty interests in both medicines. Watch Imdelltra sales outside China for current payments and olpasiran’s development for future royalty potential.
Ionis sold Royalty Pharma a minority share of future Spinraza and pelacarsen royalties for $500 million upfront, so both participate in those medicines’ success. Watch pelacarsen approval and sales milestones: they determine additional payments to Ionis, with some subject to deadlines.
Exelixis relies mainly on cabozantinib revenue and pays Royalty Pharma 3% of its partners’ net sales of cabozantinib medicines. Watch those sales outside the U.S.: Ipsen sells outside the U.S. and Japan, while Takeda sells in Japan.
Syndax received $350 million from Royalty Pharma in return for 13.8% of U.S. Niktimvo net sales, subject to adjustments, until payments reach $822.5 million. Its U.S. Niktimvo sales, co-commercialized with Incyte, show how quickly Royalty Pharma receives payments toward that cap.
Ascendis received $300 million from Royalty Pharma in exchange for capped shares of U.S. SKYTROFA and YORVIPATH sales. Watch U.S. net revenue from each medicine: Royalty Pharma receives 9.15% from SKYTROFA and 3% from YORVIPATH under the separate agreements.
Ultragenyx sells Crysvita, whose sales and forecasts affect both Royalty Pharma’s royalty receipts and the value of its royalty assets. Lower Crysvita forecasts contributed to Royalty Pharma’s expense for reduced expected cash flows in 2024.
Takeda’s Entyvio sales and Japanese cabozantinib sales support Royalty Pharma’s royalties. Watch Entyvio’s sales for ulcerative colitis and Crohn’s disease, and Japanese cabozantinib sales, on which Exelixis pays Royalty Pharma a share.
Gilead sells Trodelvy, and those medicine sales generate royalty receipts for Royalty Pharma. Trodelvy sales are the Gilead revenue line to watch for this connection.
Novartis AG earningsNVS
Novartis sells Promacta, which generated $142 million of Royalty Pharma receipts in 2025, so its report will show whether sales continue to support that royalty stream.
Look at Novartis's reported Promacta sales, not just its company-wide results. Growth or stability would support Royalty Pharma's sales-based receipts from the medicine; a decline would weaken the product base behind those receipts.
GSK plc earningsGSK
GSK sells Trelegy, which generated $332 million of Royalty Pharma receipts in 2025, so its report will show whether this major royalty stream has a firm sales base.
Look at GSK's reported Trelegy sales, not just its company-wide results. Growth or stability in Trelegy would support Royalty Pharma's sales-based receipts from the medicine; a decline would point more directly to pressure on this significant income stream.
Biogen Inc. earningsBIIB
Biogen sells Tysabri and Spinraza, which generate royalties for Royalty Pharma, and its report also updates the development of litifilimab, which Royalty Pharma funded.
Separate Tysabri and Spinraza sales from litifilimab's development: the first two affect Royalty Pharma's current royalties, while the latter concerns a medicine still in development. Stronger sales would support current receipts and development progress would preserve future potential; weaker sales or stalled development would weaken those two paths, respectively.
Fed Interest Rate Decision
Royalty Pharma earns royalties when its partners’ therapies sell, while its $380 million term loan costs SOFR plus 1.25%; Fed rate changes can shift floating-rate borrowing costs and returns on variable-rate investments.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher-than-expected rates can raise the cost of Royalty Pharma’s SOFR-linked term loan and other repricing debt, reducing cash available from portfolio receipts for operations and new investments; variable-rate investment returns may partly offset the increase.
If it comes in below expectations
Lower-than-expected rates can reduce interest costs on Royalty Pharma’s SOFR-linked term loan and other repricing debt, leaving more cash for operations and new investments; they may also lower returns on variable-rate investments.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda sells Entyvio and cabozantinib in Japan, and its report can show whether sales of these medicines support the related Royalty Pharma royalties.
Read Entyvio sales separately from cabozantinib sales in Japan. Stronger sales of either medicine would support the corresponding Royalty Pharma receipts; weakness in one would pressure that royalty stream, not automatically the other.
Ligand Pharmaceuticals Inc. earningsLGND
Ligand also funds drug developers and buys royalty rights, so its investment activity shows how much competition Royalty Pharma may face for attractive deals.
Look at how much capital Ligand commits and which royalty rights or development programs it backs. Active investment would show that Royalty Pharma faces another buyer competing for a limited pool of attractive deals; limited investment would offer less evidence of that pressure, but would not prove Royalty Pharma can secure deals more easily.
ABBVIE INC. earningsABBV
AbbVie co-markets Imbruvica with Johnson & Johnson; the medicine generated $170 million of Royalty Pharma receipts in 2025, and its sales will show whether competition is weakening that stream.
Focus on Imbruvica sales, not AbbVie's total revenue, and consider the competition from other blood-cancer treatments. Stable sales would support Royalty Pharma's royalty receipts; falling sales would show that competitive pressure on the medicine is reaching those receipts.
Vertex Pharmaceuticals Inc earningsVRTX
Vertex sells the cystic-fibrosis medicines behind Royalty Pharma's largest royalty franchise, and its report also bears on the dispute over Alyftrek payments.
Watch cystic-fibrosis medicine sales and what Vertex reports about Alyftrek sales relevant to the royalty dispute. Steady sales and clearer information on Alyftrek payments would support Royalty Pharma's largest royalty stream; weaker sales or continued uncertainty over the disputed amounts would leave that major source of receipts less secure.
Pfizer Inc. earningsPFE
Pfizer co-markets Xtandi with Astellas; the medicine generated $197 million of Royalty Pharma receipts in 2025, making Pfizer's report a read on this royalty stream's sales base.
Watch Pfizer's reported Xtandi sales and related outlook, rather than treating Pfizer's overall results as a proxy for the medicine. Stronger sales would support Royalty Pharma's royalties; weaker sales or lower expectations would weigh on both receipts and expected future cash flows.
Ultragenyx Pharmaceutical Inc. earningsRARE
Ultragenyx sells Crysvita, whose sales and forecasts affect Royalty Pharma's receipts and the value of its royalty asset, so its report offers evidence on both.
Separate Crysvita's reported sales from Ultragenyx's expectations for future sales: sales drive Royalty Pharma's receipts, while changed expectations affect the royalty asset's expected cash flows. Stronger sales and expectations would support both current receipts and the asset's cash-flow base; weaker sales or lower expectations would put them under pressure.
Royalty Pharma plc earningsThis company
Royalty Pharma collects cash tied to medicine sales, and its report will show whether receipts are growing across the portfolio rather than just accounting income.
Read Royalty Receipts—the sales-based payments—beside Portfolio Receipts, which also include milestones and other contractual payments, and distinguish both from accounting income on financial royalty assets, which can move with cash-flow expectations without matching cash received. Rising Royalty Receipts beyond the cystic-fibrosis franchise would show that sales across more products are supporting cash generation; if total receipts rise mainly on milestones while Royalty Receipts are flat or falling, the core sales-based cash engine is not improving in step, leaving less evidence of cash to fund investments and debt service.
